Clostast (Clopidogrel Hydrogen Sulfate)

Adult dosage

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start treatment on the first day with a loading dose of 300 mg once daily, followed by a maintenance dose of 75 mg orally once daily. In this case, aspirin 75 ～ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer this medicine 75 mg orally once daily. In this case, aspirin 75 ～ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be administered with or without food.

This medication is an agent that prevents platelets from aggregating, thereby preventing blood clotting. The effectiveness of this medication may be diminished in individuals who genetically have reduced function of the CYP2C19 enzyme; therefore, alternative treatment options should be considered in such cases. Moreover, co-administration with medications that increase the activity of the CYP2C19 enzyme may elevate the concentration of this drug, increasing the risk of bleeding, so it is advisable not to combine them. Patients with allergies to this drug, those who are bleeding, patients with severe liver damage, nursing women, and individuals with lactose-related genetic disorders should not take this medication. Patients at high risk of bleeding or with blood disorders, and those scheduled for surgery should use this medication with caution, and if bleeding symptoms occur, they should promptly inform their healthcare provider. The risk of bleeding may increase when this medication is taken with other anticoagulants, non-steroidal anti-inflammatory drugs, or selective serotonin reuptake inhibitors, so caution is advised. During pregnancy, there is a low risk to the fetus, but caution should be taken due to the risk of bleeding during delivery, and during breastfeeding, this drug may be secreted in breast milk, so consideration should be given to stopping breastfeeding or discontinuing the medication. The safety and efficacy of this drug in pediatrics have not been established, and caution is needed for elderly patients or those with reduced renal or hepatic function, as bleeding risk may be heightened. In cases of overdose, bleeding may worsen, and immediate medical treatment is required, as platelet transfusions may be necessary to reverse the effects of this drug. During treatment, it may take longer for bleeding to stop; thus, patients should immediately inform their doctor if bleeding persists or if there are signs of ongoing bleeding. This medication should be stored out of reach of children, and transferring it to another container should be avoided as it may cause accidents or degradation in quality.

Hemorrhage, gastrointestinal hemorrhage, hemorrhage requiring hospitalization, purpura, contusion, hematoma, epistaxis, hematoma, hematuria, intraocular hemorrhage, intracranial hemorrhage, major hemorrhage, life-threatening hemorrhage, fatal hemorrhage, hemorrhagic stroke, need for anticoagulant medication, need for transfusion, significant functional impairment, intraocular hemorrhage accompanied by significant vision loss, minor hemorrhage, severe neutropenia, aplastic anemia, severe thrombocytopenia, thrombocytopenia, agranulocytosis, gastrointestinal symptoms, abdominal pain, dyspepsia, gastroenteritis, constipation, diarrhea, rash, pruritus, depression, upper respiratory tract infection, dyspnea, rhinitis, bronchitis, cough, urinary tract infection, purpura disease, bloody stool, thrombocytopenia, pneumonia, sinusitis, eczema, skin ulcer, cystitis, cataract, conjunctivitis, allergy symptoms, ischemic necrosis, hemorrhagic gastritis, duodenal ulcer, gastric ulcer, perforated gastric ulcer, upper gastrointestinal ulcer bleeding, flatulence, hyperbilirubinemia, infectious hepatitis, fatty liver, hemorrhagic arthropathy, hematuria syndrome, hemoptysis, retroperitoneal hemorrhage, pulmonary hemorrhage, vasculitis, hypotension, bronchospasm, interstitial pneumonia, eosinophilic pneumonia, colitis, pancreatitis, gastritis, stomatitis, hepatitis, acute liver failure, petechial eruption, erythematous skin rash, urticaria, itching, angioedema, vesicular dermatitis, drug-induced hypersensitivity syndrome, eosinophilia, drug rash, lichen planus, arthralgia, arthritis, myalgia, glomerulopathy, gynecomastia, fever, abnormal liver function tests, elevated blood creatinine, decreased motor function, tremor, voice disorders, abnormal gait, hyperkinesia, ataxia, paresthesia, insomnia, depression, amnesia, anxiety, hypomania, cognitive disturbances, abnormal behavior, chest pain, weight loss, weight gain, facial flushing, weakness, rigidity, facial swelling, syncope, bloody stool, cerebral hemorrhage, hematoma, gingival bleeding, cough, dyspnea, visual disturbances, visual field defects, dry eye syndrome, transient blindness, congestion, tinnitus, dysgeusia, urinary disorders, polyuria syndrome, non-protein nitrogen elevation, uremia, increased blood urea nitrogen, hypoglycemia, hyperuricemia, elevated liver enzymes, increased ALT, liver function abnormalities, leg edema, arrhythmia, bradycardia, palpitations, rash, itching, contact dermatitis, gynecomastia, elevated PSA, cholecystitis, hematemesis, spinal hematoma

This medication should be stored in a tightly sealed container to protect it from air and light exposure. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance

Pink circular film-coated tablet

Package unit

30 tablets/bottle, 200 tablets/bottle